DK1707562T3 - Krystallinsk v-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famaceutiske sammensætninger, som indeholder denne - Google Patents

Krystallinsk v-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famaceutiske sammensætninger, som indeholder denne

Info

Publication number
DK1707562T3
DK1707562T3 DK06290328T DK06290328T DK1707562T3 DK 1707562 T3 DK1707562 T3 DK 1707562T3 DK 06290328 T DK06290328 T DK 06290328T DK 06290328 T DK06290328 T DK 06290328T DK 1707562 T3 DK1707562 T3 DK 1707562T3
Authority
DK
Denmark
Prior art keywords
crystalline
preparation
pharmaceutical compositions
compositions containing
ivabradine hydrochloride
Prior art date
Application number
DK06290328T
Other languages
English (en)
Inventor
Stephane Horvath
Marie-Noelle Auguste
Gerard Damien
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34954955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1707562(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Application granted granted Critical
Publication of DK1707562T3 publication Critical patent/DK1707562T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • G—PHYSICS
    • G04—HOROLOGY
    • G04F—TIME-INTERVAL MEASURING
    • G04F1/00—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
    • G04F1/04—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity
    • G04F1/06—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity by flowing-away of a prefixed quantity of fine-granular or liquid materials, e.g. sand-glass, water-clock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/214—Monitoring or handling of messages using selective forwarding
    • H—ELECTRICITY
    • H04—ELECTRIC COMMUNICATION TECHNIQUE
    • H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
    • H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
    • H04L51/21—Monitoring or handling of messages
    • H04L51/212—Monitoring or handling of messages using filtering or selective blocking

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Signal Processing (AREA)
  • Computer Networks & Wireless Communication (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK06290328T 2005-02-28 2006-02-28 Krystallinsk v-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famaceutiske sammensætninger, som indeholder denne DK1707562T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0501989A FR2882555B1 (fr) 2005-02-28 2005-02-28 Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
DK1707562T3 true DK1707562T3 (da) 2008-10-13

Family

ID=34954955

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06290328T DK1707562T3 (da) 2005-02-28 2006-02-28 Krystallinsk v-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famaceutiske sammensætninger, som indeholder denne

Country Status (42)

Country Link
US (3) US7361650B2 (da)
EP (1) EP1707562B1 (da)
JP (1) JP4628974B2 (da)
KR (1) KR100835447B1 (da)
CN (1) CN100402502C (da)
AP (1) AP1956A (da)
AR (1) AR052926A1 (da)
AT (1) ATE396974T1 (da)
BR (1) BRPI0600796B8 (da)
CA (1) CA2537400C (da)
CO (1) CO5770097A1 (da)
CR (1) CR8249A (da)
CU (1) CU23616B7 (da)
CY (1) CY1109010T1 (da)
DE (1) DE602006001312D1 (da)
DK (1) DK1707562T3 (da)
EA (1) EA008465B1 (da)
ES (1) ES2308689T3 (da)
FR (1) FR2882555B1 (da)
GE (1) GEP20084467B (da)
GT (1) GT200600088A (da)
HK (1) HK1096659A1 (da)
HR (1) HRP20080406T5 (da)
IL (1) IL173959A0 (da)
JO (1) JO2515B1 (da)
MA (1) MA28134A1 (da)
ME (1) ME02747B (da)
MY (1) MY158129A (da)
NO (1) NO338481B1 (da)
NZ (1) NZ545578A (da)
PE (1) PE20061142A1 (da)
PL (1) PL1707562T3 (da)
PT (1) PT1707562E (da)
RS (1) RS50598B (da)
SA (1) SA06270040B1 (da)
SG (1) SG125229A1 (da)
SI (1) SI1707562T1 (da)
TW (1) TWI314143B (da)
UA (1) UA86595C2 (da)
UY (1) UY29406A1 (da)
WO (1) WO2006092492A1 (da)
ZA (1) ZA200601764B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en) 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
US8212026B2 (en) 2007-05-30 2012-07-03 Ind-Swift Laboratories Limited Process for the preparation of ivabradine hydrochloride and polymorph thereof
WO2010072409A1 (en) 2008-12-22 2010-07-01 Krka, D. D., Novo Mesto Process for preparation of ivabradine
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
EP2902384B1 (en) 2010-02-12 2017-11-08 KRKA, D.D., Novo Mesto Form of ivabradine hydrochloride
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
TWI499587B (zh) * 2010-06-03 2015-09-11 Jiangsu Hengrui Medicine Co 硫酸伊伐佈雷定及其ｉ型結晶的製備方法
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
EP2726462B1 (en) 2011-08-02 2017-03-22 Sandoz AG Acetone solvate of ivabradine hydrochloride
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
US9120755B2 (en) 2011-11-14 2015-09-01 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
CN103183639B (zh) * 2011-12-30 2015-06-17 浙江京新药业股份有限公司 一种稳定的盐酸伊伐布雷定ii晶型及其制备方法
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
EP2781509B2 (en) * 2013-03-19 2023-06-14 Chemo Research, S.L. New polymorph of ivabradine hydrochloride and method for its preparation
ITMI20130416A1 (it) * 2013-03-19 2014-09-20 Chemo Res S L Nuovo polimorfo del cloridrato di ivabradina e metodo per la sua preparazione
CZ305096B6 (cs) 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
ES2672472T3 (es) 2013-12-12 2018-06-14 Synthon Bv Composición farmacéutica que comprende ivabradina amorfa
EP2774606B1 (en) 2014-02-14 2019-01-30 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV
CZ305436B6 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2017173458A1 (en) * 2016-04-01 2017-10-05 Swiderski Cyprianna Compositions and methods targeting hcn channels for breathing therapeutics
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
US20230181472A1 (en) 2018-10-30 2023-06-15 Amgen Inc. Process of making ivabradine hydrochloride drug product
CA3161960A1 (en) 2019-12-16 2021-06-24 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef)
IT202000025312A1 (it) 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490369A (en) * 1981-05-19 1984-12-25 Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung Benzazepine derivatives, their pharmaceutical compositions and method of use
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891827B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
EP1707562A1 (fr) 2006-10-04
US20060194963A1 (en) 2006-08-31
SG125229A1 (en) 2006-09-29
JP4628974B2 (ja) 2011-02-09
PT1707562E (pt) 2008-07-08
NO338481B1 (no) 2016-08-22
KR20060095499A (ko) 2006-08-31
TW200640872A (en) 2006-12-01
AP2006003521A0 (en) 2006-02-28
CR8249A (es) 2008-01-21
WO2006092492A1 (fr) 2006-09-08
TWI314143B (en) 2009-09-01
EA008465B1 (ru) 2007-06-29
IL173959A0 (en) 2006-07-05
NO20060948L (no) 2006-08-29
UY29406A1 (es) 2006-07-31
EA200600320A1 (ru) 2006-08-25
MY158129A (en) 2016-08-30
US20090318417A1 (en) 2009-12-24
FR2882555B1 (fr) 2007-05-04
US7361650B2 (en) 2008-04-22
BRPI0600796A (pt) 2007-08-14
US20080153803A1 (en) 2008-06-26
UA86595C2 (ru) 2009-05-12
GEP20084467B (en) 2008-08-25
SA06270040B1 (ar) 2010-03-23
US7867996B2 (en) 2011-01-11
HRP20080406T5 (en) 2008-11-30
CU20060037A7 (es) 2008-06-30
PL1707562T3 (pl) 2008-08-29
EP1707562B1 (fr) 2008-05-28
GT200600088A (es) 2006-10-24
CA2537400A1 (fr) 2006-08-28
CN100402502C (zh) 2008-07-16
ES2308689T3 (es) 2008-12-01
ME02747B (me) 2010-05-07
CY1109010T1 (el) 2014-07-02
ATE396974T1 (de) 2008-06-15
AP1956A (en) 2009-02-18
CA2537400C (fr) 2009-12-15
JO2515B1 (en) 2010-03-17
BRPI0600796B1 (pt) 2019-02-19
CO5770097A1 (es) 2007-06-29
MA28134A1 (fr) 2006-09-01
DE602006001312D1 (de) 2008-07-10
HK1096659A1 (en) 2007-06-08
AU2006200857A1 (en) 2010-01-28
JP2006241156A (ja) 2006-09-14
PE20061142A1 (es) 2006-12-30
CU23616B7 (es) 2011-01-27
RS50598B (sr) 2010-05-07
FR2882555A1 (fr) 2006-09-01
KR100835447B1 (ko) 2008-06-09
ZA200601764B (en) 2007-05-30
BRPI0600796B8 (pt) 2021-05-25
NZ545578A (en) 2007-02-23
HRP20080406T3 (en) 2008-09-30
SI1707562T1 (sl) 2008-10-31
AR052926A1 (es) 2007-04-11
CN1827602A (zh) 2006-09-06

Similar Documents

Publication Publication Date Title
DK1707562T3 (da) Krystallinsk v-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famaceutiske sammensætninger, som indeholder denne
DK1695709T3 (da) Krystalinsk gammad-form af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
DK1695710T3 (da) Krystallinsk betad-form af ivabradinhydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
DK1695965T3 (da) Krystallinsk betaform af ivabradin-hydrochlorid, fremgangsmåde til fremstilling heraf og famceutiske sammensætninger indeholdende denne
DK1752443T3 (da) Ny krystallinsk form V af agomelatin, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende dette
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
IL178545A0 (en) ??d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
AP2303A (en) d-Crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it.
RS55499B1 (sr) Novi kristalni oblik iii agomelatina, postupak njegove proizvodnje i farmaceutske kompozicije koje ga sadrže
DK1457208T3 (da) Fremgangsmåde og farmaceutiske præparater til pålidelig opnåelse af acceptable serumtestosteronniveauer
NO20054876D0 (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
DK2036892T3 (da) 1,2,4,5-tetrahydro-3H-benzazepinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
WO2006090268A3 (en) Processes for the preparation of alfuzosin and salts thereof and novel crystalline forms of alfuzosin
WO2008051564A3 (en) Crystalline forms of palonosetron hydrochloride
DK1707564T3 (da) Indanyl-piperazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
DK2402306T3 (da) Fremgangsmåde til fremstilling af 5-aminolaevulinsyrehydrochlorid
NO20055167D0 (no) Nye benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20043188L (no) Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
DK1853220T3 (da) Fremgangsmåde til fremstilling af tabletter indeholdende inflammationshæmmende non-steroid-lægemiddel, deres sammensætninger og medicinske anvendelse
NO20050391D0 (no) Nye fluorinerte benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20043880L (no) Nye benzoindolinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20055124D0 (no) Nye benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
AU2006200857B2 (en) y-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
AU2006200854B2 (en) bd-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it
AU2006200856B2 (en) beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it